β- Adrenoceptors blockers

Prof. Hanan Hagar Pharmacology Unit College of Medicine

Classification of β - Adrenoceptors Blockers

Selective \$1 antagonists
Atenolol, Acebutolol,
Bisoprolol, Esmolol,
Metoprolol

Non selective β- Antagonists
Blocks β1& β2 receptors
Propranolol, Pindolol
Sotalol, Timolol (PST)

Mixed α, β receptors blockers

- Carvedilol
- > Labetalol

B ADRENOCEPTOR BLOCKERS

Pharmacodynamic Classification

According to selectivity

Non-Selective

Block β_1 & β_2

Selective

Block β₁

Propranolol, Sotalol, Timolol (Eye) Atenolol, Bisoprolol, Metoprolol, Esmolol

Labetalol, Carvedilol (mixed α , β blockers)

According to presence of agonistic/antagonistic action; Intrinsic Sympathomimetic Activity (ISA)



Atenolol, Bisoprolol, Metoprolol Propranolol, Sotalol, Timolol, carvedilol With ISA (may activate beta receptors)

labetalol


According to presence of membrane stabilizing effects i.e. Block Na Channels

Propranolol, labetalol

Quinidine-like action Antiarrythmic action

β ADRENOCEPTOR BLOCKERS

Pharmacokinetic Classification



According to their lipid solubility




	Lipophilic	Hydrophilic
Oral absorption	Complete	Irregular
Liver metabolism	Yes	No
t _{1/2}	Short	Long
CNS side effects	High	low
	Metoprolol Propranolol, Timolol Labetalol , Carvedilol	Atenolol, Bisprolol, Esmolol Sotalol

CNS depressant effects i.e. Sedative effect → **↓** Anxiety

Pharmacokinetis of β -blockers:

- Most of them are lipid soluble
- Lipid soluble β–blockers
 - well absorbed orally.
 - are rapidly distributed, cross readily BBB
 - Have CNS depressant actions
 - Metoprolol, propranolol, timolol, labetalol, carvedilol
- Most of them have half-life from 3-10 hrs except Esmolol (10 min. given intravenously).
- Most of them metabolized in liver & excreted in urine.

Half lives for some \(\beta \)—blockers



<u>β–Adrenergic receptors :</u>

β_1 (Heart):

- \triangleright Increase heart Rate \rightarrow Positive chronotropic effect.
- \triangleright Increase in contractility \rightarrow Positive inotropic action.
- \triangleright Increase in conduction velocity \rightarrow Positive dromotropic.
- β_2 relaxation of smooth muscles
- β₂: Hyperglycemia
- β_2 : \uparrow Release of glucagon from pancreas
- β₂ α1: Glycogenolysis & gluconeogenesis in liver
- **B3**: \(\backsquare{\text{Lipolysis}}\) Lipolysis by adipose tissue
- **Pre-synaptic β2 Receptors:** ↑ release of NE
- (Positive feed back mechanism).

B Receptor location

Receptor	Location
β1	Heart, JG cells in kidney
β2	Bronchi, blood vessels, liver, skeletal muscle
β3	Adipose tissue

TISSUE	RECEPTOR TYPE	ACTION
HeartSinus and AVConduction pathwayMyocardial fibrils	β1 β1 β1	↑Automaticity ↑Conduction velocity, automaticity ↑Contractility, automaticity
Vascular smooth muscle	β2	Vasodilation
Bronchial smooth muscle	β2	Bronchodilation
Kidneys	β1	↑Renin release
Liver	β2	↑Glycogenolysis and gluconeogenesis
Adipose tissue	β3	↑Lipolysis
Skeletal muscle	β2	Tremor

<u>Pharmacological actions of β–Adrenergic blockers:</u> CVS:

Negative inotropic, chronotropic, dromotropic → → CO


Antianginal effects (ischemic heart disease):

- ↓ Heart rate (bradycardia)
- ↓ force of contraction → ↓ cardiac work
- ↓ Oxygen consumption due to bradycardia

Anti-arrhythmic effects:

→excitability, **→** automaticity & **→** conductivity (due to its sympathetic blocking).

All β -Adrenergic blockers mask hypoglycemic manifestations in diabetic patients \rightarrow COMA



Pharmacological actions of \(\beta\)—Adrenergic blockers:

Blood vessels β_2

- lacktriangle peripheral resistance (PR) by blocking vasodilatory effect eta_2
- **♦** blood flow to organs **♦** cold extremities


contraindicated in peripheral diseases like Reynaud's disease

Blood pressure

Antihypertensive → → BP in hypertensive patients due to effects on:

- **4** Inhibiting heart properties → **4** cardiac output ($β_1$)
- lacktriangle lacktriangle renin secretion lacktriangle Ang II & aldosterone secretion (eta_1) .
- Presynaptic inhibition of NE release from adrenergic nerves

Renin-angiotensin-aldosterone system



Pharmacological actions of \(\beta - Adrenergic blockers: \)

Respiratory tract: β_2

- Bronchoconstriction
- contraindicated in asthmatic patients.

Eye:

- **↓** aqueous humor production from ciliary body
- **↓** Reduce intraocular pressure (IOP)
- e.g. timolol as eye drops

Intestine:

↑ Intestinal motility

Pharmacological actions of β -Adrenergic blockers: Metabolic effects:

- Hypoglycemia
 - **↓** glycogenolysis in liver
 - **↓** glucagon secretion in pancreas
- ↓ lipolysis in adipocytes
- Na⁺ retention 2^{ndry} to →BP → renal perfusion

Clinical Uses of β -receptor blockers

- Cardiovascular disorders
 - Hypertension
 - Arrhythmia
 - Angina pectoris
 - Myocardial infarction
 - Congestive heart failure
- Pheochromocytoma
- Chronic glaucoma
- Hyperthyroidism (thyrotoxicosis)
- Migraine headache prophylaxis
- Anxiety

Clinical Uses of β -receptor blockers

In Hypertension:

Propranolol, atenolol, bisoprolol

Labetalol: α , β blockers in hypertensive pregnant & hypertensive crisis.

In cardiac arrhythmias:

In supraventricular & ventricular arrhythmias.

Bisoprolol and carvedilol are preferred

Angina pectoris:

- ↓ heart rate, ↓ cardiac work & oxygen demand.
- \downarrow the frequency of angina episodes.

Clinical Uses of β -receptor blockers

Congestive heart failure:

e.g. carvedilol:

- -antioxidant and non selective α,B blocker
- -↓ myocardial remodeling & ↓ risk of sudden death.

Myocardial infarction:

Have cardio-protective effect

- **↓** infarct size
- **→**morbidity & mortality **→**
- **→** myocardial O2 demand.
- Anti-arrhythmic action.
- **↓** incidence of sudden death.

In glaucoma

- e.g. Timolol as eye drops
- Decreases Intraocula pressure (IOP)
- Decreases secretion of aqueous humor by ciliary body

In Hyperthyroidism

- Protect the heart against sympathetic over stimulation
- Controls symptoms; tachycardia, tremors, sweating.

In anxiety (Social and performance type)

e.g. Propranolol

Controls symptoms due to sympathetic system stimulation as tachycardia, tremors, sweating.

Migraine:

Prophylactic

- **+**reduce episodes of chronic migraine
- **↓**catecholamine-induced vasodilatation in the brain vasculature

e.g. propranolol


Pheochromocytoma


used with α -blockers (never alone)


- α-blockers lower the elevated blood pressure.
- β-blockers protect the heart from NE.

Uses of B-blockers









Adverse Effects of β - Adrenoceptors blockers

Due to blockade of β1- receptor:

Bradycardia, hypotension, heart failure

Due to blockade of β 2- receptor:

only with non-selective β blockers

- Hypoglycemia
- Bronchoconstriction (# Asthma, emphysema).
- vasoconstriction→ cold extremities & intermittent claudication
- Erectile dysfunction & impotence
- Coronary spasm → in variant angina patients
- All β-Adrenergic blockers mask hypoglycemic manifestations i.e. tachycardia, sweating,... → COMA

Intermittent claudication

Peripheral artery disease most commonly affects the <u>legs</u>, but other arteries may also be involved. The classic symptom is leg pain when walking which resolves with rest.

Risk factors:

Diabetes, hypercholesterolemia, hypertension

Adverse Effects of β - Adrenoceptors blockers


- **4** Depression, and hallucinations.
- **4** Gastrointestinal disturbances.
- **4** Sodium retention

Precautions

Sudden stoppage will give rise to a withdrawal syndrome:

- ✓ Rebound angina, arrhythmia, myocardial infarction &
- ✓ Hypertension WHY? → Up-regulation of β-receptors.
- ✓ To prevent withdrawal manifestations → drug withdrawn gradually.


Adverse effects of B-Blockers











Contraindications of β - Adrenoceptors blockers

- Heart Block (beta blockers can precipitate heart block).
- Bronchial Asthma (safer with cardio-selective β-blockers).
- Peripheral vascular disease (safer with cardio-selective βblockers).
- Diabetic patients → Masking of hypoglycemia / GIVEN
 CAUSIOUSLY
- Hypotension
- \circ Alone in pheochromocytoma (must be given with an α -blockers).

Non-Selective Competitive Blocker of β_1 & β_2 Membrane stabilizing action/ quinidine-like /local anesthetic effect sedative actions /No ISA

Kinetics

Lipophilic, completely absorbed, 70% destroyed during 1st pass hepatic metabolism, 90-95% protein bound, cross BBB and excreted in urine.

Can be given p.o or parenteral

Dynamics

β-blocking Effect: \rightarrow (anti-arrhythmic effects).

Membrane Stabilization: Block Na channels → has local anesthetic effect direct depressant to myocardium → (anti-arrhythmic effects).

PROPRANOLOL

Actions

Heart: by block $β_1$

- Inhibit heart properties → **+** cardiac output
- Has anti-ischemic action \rightarrow \downarrow cardiac work + \downarrow O_2 consumption
- Has anti-arrhythmic effects → **+**excitability, automaticity & conductivity
- + by membrane stabilizing activity

BP; by block $\beta_1 \& \beta_2$

- Has antihypertensive action by →
- **♣** Inhibiting heart properties **▶ ♦** cardiac output
- **♣** B blockade : **♦** renin & RAAS system
- **4** Presynaptic inhibition of NE release from adrenergic nerves
- Inhibiting sympathetic outflow in CNS

PROPRANOLOL

Actions

Mainly by β_2 blockade

Blood Vessels: Vasoconstriction → ↓ blood flow specially to muscles, other organs except brain → cold extremities

Bronchi: Bronchospasm specially in susceptible patients

Intestine: 1 Intestinal motility

Metabolism:

In adipocytes:

LipoTysis

On peripheral & central nervous systems:

Has local anesthetic effect

tremors &

anxiety

PROPRANOLOL

INDICATIONS

- **4** Hypertension
- **Arrhythmias**
- Angina
- Myocardial infarction
- **4**Migraine [Prophylaxis]
- \blacksquare Pheochromocytoma; used with α -blockers (never alone)
- **4** Chronic glaucoma
- **Tremors**
- Anxiety: (specially social & performance type)
- Hyperthyroidism

Selective \(\beta 1\)- receptor blockers

- Selectivity present in low doses but is lost at high doses
- no change in lipid or glucose
- no bronchoconstriction
- No effect on peripheral resistnce
- Selective β1- receptor blockers are preferable in hypertensive patients with:
 - Asthma, COPD
 - Raynaud's phenomenon & peripheral vascular disease (PVD).
 - Diabetics/ Dyslipidemias.
 - Variant Angina (coronary spasm).

α and β - Adrenoceptors blockers

Labetalol and Carvedilol

- \checkmark Non selective β blockers with concurrent α_1 blocking action.
- ✓ Produce peripheral vasodilation
- ✓ Decrease blood pressure
- ✓ Used in the treatment of hypertensive emergencies as they can rapidly lower BP.

LABETALOL

Blocks $\alpha_1 \& \beta$

- ✓ Rapid acting, non-selective
- ✓ has ISA and local anesthetic effect.
- ✓ Given p.o and i.v.

Uses

- ✓ Severe hypertension in pheochromocytoma
- ✓ Hypertensive crisis (e.g. during abrupt withdrawal of clonidine).
- ✓ Used in pregnancy-induced hypertension

Adverse effects:

Orthostatic hypotension, sedation & dizziness

CARVEDILOL

Blocks $\alpha_1 \& \beta$

- ✓ Non-selective with no ISA & no local anesthetic effect.
- ✓ Has ANTIOXIDANT action
- ✓ Used effectively in → CONGESTIVE HEART FAILURE → reverses its pathophysiological changes.
- ✓ Adverse effects:

Orthostatic hypotension, Edema

Summary of B-blockers uses

- Hypertension Atenolol, Bisoprolol, Metoprolol, Propranolol
- o cardiac arrhythmia Esmolol (ultra-short acting), Atenolol, Propranolol
- o **Congestive heart failure** Carvedilol, Bisoprolol, Metoprolol
- Myocardial infarction Atenolol, Metoprolol, Propranolol
- Glaucoma Timolol
- Migraine prophylaxis Propranolol
- o Relief of anxiety (social & performance) Propranolol
- o Thyrotoxicosis Propranolol

B-receptor blockers

Propranolol

Carvedilol

Labetalol

	$B_{1,} \beta_2$ blocker	Hyperthyroidism (thyrotoxicosis) Relieve anxiety (social performance)
Timolol	$B_{1,}\beta_{2}$ blocker	Glaucoma
Atenolol Bisoprolol Metoprolol	B ₁ blocker	Myocardial infarction Hypertension
Esmolol	B ₁ blocker	Cardiac arrhythmia

Congestive heart failure

Hypertension in pregnancy

Hypertensive emergency

Non selective Migraine prophylaxis

Ultra short

a, B blocker

a, B blocker

acting